Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
adolescence
childhood
psoriasis
therapy
treatment
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
07
07
2019
revised:
31
08
2019
accepted:
20
09
2019
pubmed:
4
10
2019
medline:
13
5
2020
entrez:
4
10
2019
Statut:
ppublish
Résumé
The objective of this study is to determine drug effectiveness and safety of the tumor necrosis factor-alpha blocker monoclonal antibody adalimumab in a real-life cohort of 54 children and/or adolescents with severe plaque psoriasis. Retrospective, multicenter analysis over a 52-week period is discussed in this study. Efficacy was determined by the percentage of patients achieving Psoriasis Area Severity Index (PASI 75) and PASI 90 at weeks 16, 24, and 52 and the response in biologic-naïve versus non-naïve patients. Safety was assessed by the number of patients experiencing at least one adverse event. At week 16, 29.6% of patients achieved a 90% PASI score reduction (PASI 90), while 55.5% of patients achieved a 75% PASI score reduction (PASI 75). Effectiveness was sustained through week 24, since PASI 90 response increased to 55.5% and PASI 75 response increased to 74.0% of patients. The PASI response rates did not differ between biologic-naïve and non-naïve patients. The drug was well tolerated and no serious infections were observed. Adalimumab was effective and safe in this cohort of children with severe plaque psoriasis in a 52-week observation. Effectiveness did not differ between biologic-naïve and non-naïve patients.
Substances chimiques
Anti-Inflammatory Agents
0
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13091Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Belloni Fortina, A., Bardazzi, F., Berti, S., Carnevale, C., Di Lernia, V., El Hachem, M., … Villani, A. (2017). Treatment of severe psoriasis in children: recommendations of an Italian expert group. European Journal of Pediatrics, 176, 1339-1354.
Di Lernia, V. (2017). Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation. Expert Opinion on Biological Therapy, 17, 1553-1556.
Eichenfield, L. F., Paller, A. S., Tom, W. L., Sugarman, J., Hebert, A. A., Friedlander S. F., … Cordoro K. M. (2018). Pediatric psoriasis: Evolving perspectives. Pediatric Dermatology, 35, 170-181.
Esposito, M., Prignano, F., Rongioletti, F., Hansel, K., Bianchi, L., Pescitelli, L., … Stingeni L. (2018). Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice. The Journal of Dermatological Treatment, 6, 1-5.
European Medicines Agency 2019 https://www.ema.europa.eu/documents/productinformation/humira-epar-product-information_en.pdf
Landells, I., Marano, C., Hsu, M. C., Li, S., Zhu, Y., Eichenfield, L. F., … Randazzo, B. (2015). Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology, 73, 594-603.
Paller, A. S., Siegfried, E. C., Pariser, D. M., Rice, K. C., Trivedi, M., Iles, J., … Langley, R. G. (2016). Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology, 74, 280-287 e1-3.
Phan, C., Beauchet, A., Burztejn, A. C., Severino-Freire, M., Barbarot, S., Girard, C., … Mahé, E. (2019). Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.15579
Papp, K., Thaçi, D., Marcoux, D., Weibel, L., Philipp, S., Ghislain, P. D., … Williams, D. (2017). Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: A randomised, double-blind, phase 3 trial. Lancet, 390, 40-49.
Thaci, D., Papp, K., Marcoux, D., Weibel, L., Pinter, A., Ghislain, P. D., … Philipp, S. (2019). Sustained long-term efficacy and safety of adalimumab in pediatric patients with severe chronic plaque psoriasis from a randomised, double-blind, phase 3 study. The British Journal of Dermatology. https://doi.org/10.1111/bjd.18029 [Epub ahead of print].